Parameter
| Biomarker | NSE | Full name | Neuron-specific enolase | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | Macromolecule | Molecular Weight | / | Core Functional Dimensions | Prognosis, Monitoring |
| Disease | Pancreatic Neuroendocrine Tumors | Disease Subtypes | / | ||
| Organ | Pancreas | Test Sample / Technology Platform | Serum (Immunoassay) | ||
| Pathobiological Mechanisms | Neuroendocrine cell-specific enolase, reflecting tumor burden and differentiation degree | ||||
| Clinical Availability Status | Clinical assistance: 30-50% PanNENs were elevated, and those with G3 and metastasis had higher levels. Combined with CgA, the disease progression was monitored | ||||
| Notes and Dynamics | The specificity of CgA is lower than that of CgA, and interferons such as neurogenic tumors should be excluded | ||||